Peregrine Capital Management LLC Coherus Bio Sciences, Inc. Transaction History

Peregrine Capital Management LLC

$3.18 Billion
Q3 2024

A detailed history of Peregrine Capital Management LLC transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Peregrine Capital Management LLC holds 734,877 shares of CHRS stock, worth $1.15 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

734,877

Previous 1,012,635 27.43%

Holding current value

$1.15 Million

Previous $1.75 Million 56.37%

% of portfolio

0.02%

Previous 0.05%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 24, 2024	SELL	$0.99 - $1.8 $274,980 - $499,964	-277,758 Reduced 27.43%	734,877 $764,000
Q2 2024 Jul 29, 2024	SELL	$1.58 - $2.51 $6,035 - $9,588	-3,820 Reduced 0.38%	1,012,635 $1.75 Million
Q1 2024 Apr 26, 2024	SELL	$2.02 - $3.14 $148,482 - $230,808	-73,506 Reduced 6.74%	1,016,455 $2.43 Million
Q4 2023 Jan 26, 2024	SELL	$1.59 - $3.85 $458,883 - $1.11 Million	-288,606 Reduced 20.94%	1,089,961 $3.63 Million
Q3 2023 Oct 19, 2023	SELL	$3.74 - $5.45 $220,607 - $321,473	-58,986 Reduced 4.1%	1,378,567 $5.16 Million
Q2 2023 Jul 26, 2023	BUY	$3.79 - $8.3 $1.4 Million - $3.07 Million	370,369 Added 34.71%	1,437,553 $6.14 Million
Q1 2023 Apr 26, 2023	SELL	$5.89 - $10.52 $296,255 - $529,134	-50,298 Reduced 4.5%	1,067,184 $7.3 Million
Q4 2022 Jan 10, 2023	SELL	$5.69 - $10.07 $68,985 - $122,088	-12,124 Reduced 1.07%	1,117,482 $8.85 Million
Q3 2022 Oct 26, 2022	BUY	$7.17 - $13.87 $375,141 - $725,692	52,321 Added 4.86%	1,129,606 $10.9 Million
Q2 2022 Jul 20, 2022	BUY	$5.86 - $13.23 $763,124 - $1.72 Million	130,226 Added 13.75%	1,077,285 $7.8 Million
Q1 2022 Apr 27, 2022	BUY	$10.92 - $16.41 $2.25 Million - $3.38 Million	206,139 Added 27.82%	947,059 $12.2 Million
Q4 2021 Jan 31, 2022	SELL	$15.81 - $18.99 $2.16 Million - $2.59 Million	-136,365 Reduced 15.54%	740,920 $11.8 Million
Q3 2021 Nov 02, 2021	SELL	$12.68 - $17.79 $2.29 Million - $3.21 Million	-180,589 Reduced 17.07%	877,285 $14.1 Million
Q2 2021 Aug 03, 2021	BUY	$12.95 - $15.41 $2.42 Million - $2.88 Million	187,151 Added 21.49%	1,057,874 $14.6 Million
Q1 2021 May 11, 2021	SELL	$14.42 - $21.39 $447,942 - $664,458	-31,064 Reduced 3.44%	870,723 $12.7 Million
Q4 2020 Jan 19, 2021	BUY	$16.56 - $18.94 $6.24 Million - $7.14 Million	376,895 Added 71.8%	901,787 $15.7 Million
Q3 2020 Oct 20, 2020	BUY	$17.41 - $19.89 $1.39 Million - $1.58 Million	79,635 Added 17.89%	524,892 $9.63 Million
Q2 2020 Jul 30, 2020	BUY	$14.43 - $19.16 $91,861 - $121,972	6,366 Added 1.45%	445,257 $7.95 Million
Q1 2020 Apr 17, 2020	SELL	$11.67 - $22.53 $58,011 - $111,996	-4,971 Reduced 1.12%	438,891 $7.12 Million
Q4 2019 Jan 16, 2020	BUY	$16.33 - $21.37 $3.38 Million - $4.42 Million	206,771 Added 87.21%	443,862 $7.99 Million
Q3 2019 Oct 16, 2019	BUY	$16.3 - $23.37 $3.86 Million - $5.54 Million	237,091 New	237,091 $4.8 Million

Others Institutions Holding CHRS

# of Institutions

135

Shares Held

77.9M

Call Options Held

40.7K

Put Options Held

50.1K

View Full List

About Coherus BioSciences, Inc.

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $122M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

More about CHRS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Peregrine Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Peregrine Capital Management LLC with notifications on news.

Account

Peregrine Capital Management LLC Coherus Bio Sciences, Inc. Transaction History